TABLE 4.
The top overrepresented pathways identified through impact analysis of DEGs in the casesT1-casesT2 comparison.
| Pathway | Pathway ID | No. of genes (DE/All) | p-value | Overrepresented genes on pathway |
| Neutrophil degranulation | R-HSA-6798695 | 43/480 | 4.44 e-16 | CDA, ORM1, TNFAIP6, HP, SLC2A3, CXCL1, GPR84 |
| Signaling by interleukins | R-HSA-449147 | 33/639 | 9.88 e-7 | CXCL8, CEBPD, IL1R1, IL1R2, IL34, ALOX15, OSM, IL5RA, CXCL1, IRS2, FOS |
| Il-4 and Il-13 signaling | R-HSA-6785807 | 16/211 | 8.33 e-6 | SOCS3, IL1A, CXCL8, CEBPD, BCL6, ALOX15, OSM, FOS, PTGS2, MMP9 |
| Immune system | R-HSA-168256 | 87/2,869 | 3.23 e-5 | CDA, ORM1, CXCL8, TNFAIP6, HP, IL5RA, SLC2A3, CXCL1, IRS2, PYGL |
| Il-10 signaling | R-HSA-6783783 | 9/86 | 7.75 e-5 | IL1A, CXCL8, IL1R1, IL1R2, CXCL1, FPR2, PTGS2 |
| TNF signaling | KEGG–4668 | 7/110 | 0.0006 | MMP9, SOCS3, FOS, PTGS2, CXCL1, CREB6, IL18R1 |